Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy

丝氨酸合成途径抑制与膳食中丝氨酸和甘氨酸的限制协同作用,用于癌症治疗。

阅读:2
作者:Mylène Tajan,Marc Hennequart,Eric C Cheung,Fabio Zani,Andreas K Hock,Nathalie Legrave,Oliver D K Maddocks,Rachel A Ridgway,Dimitris Athineos,Alejandro Suárez-Bonnet,Robert L Ludwig,Laura Novellasdemunt,Nikolaos Angelis,Vivian S W Li,Georgios Vlachogiannis,Nicola Valeri ,Nello Mainolfi,Vipin Suri,Adam Friedman,Mark Manfredi,Karen Blyth,Owen J Sansom,Karen H Vousden  0

Abstract

Many tumour cells show dependence on exogenous serine and dietary serine and glycine starvation can inhibit the growth of these cancers and extend survival in mice. However, numerous mechanisms promote resistance to this therapeutic approach, including enhanced expression of the de novo serine synthesis pathway (SSP) enzymes or activation of oncogenes that drive enhanced serine synthesis. Here we show that inhibition of PHGDH, the first step in the SSP, cooperates with serine and glycine depletion to inhibit one-carbon metabolism and cancer growth. In vitro, inhibition of PHGDH combined with serine starvation leads to a defect in global protein synthesis, which blocks the activation of an ATF-4 response and more broadly impacts the protective stress response to amino acid depletion. In vivo, the combination of diet and inhibitor shows therapeutic efficacy against tumours that are resistant to diet or drug alone, with evidence of reduced one-carbon availability. However, the defect in ATF4-response seen in vitro following complete depletion of available serine is not seen in mice, where dietary serine and glycine depletion and treatment with the PHGDH inhibitor lower but do not eliminate serine. Our results indicate that inhibition of PHGDH will augment the therapeutic efficacy of a serine depleted diet.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。